NPCE reports 21% revenue growth; FDA IGE approval could lift market
NPCE said it delivered 21% revenue growth and a robust patient pipeline. It cited FDA approval for IGE that could expand the addressable market by 20%, alongside AI-driven tools and remote monitoring.